Sumitovant Biopharma and its Portfolio of Companies Announce Milestone Highlights from the Third Quarter of FY2021

Sumitomo Dainippon Pharma and Sumitovant announced the launch of a phase 1 study of a new drug candidate for carbapenem-resistant bacterial infections. Two publications on Urovant’s FDA-approved OAB therapy, GEMTESA® (vibegron), showed clinical effectiveness and safety in patients with overactive bladder (OAB). Spirovant presented data on an investigational novel recombinant adeno-associated virus gene therapy at […]

Urovant Sciences Announces Publication of New Review of Efficacy and Safety Data for GEMTESA® (vibegron) 75 mg in Overactive Bladder Patients in the Journal Therapeutics and Clinical Risk Management

Review article in a peer-reviewed journal examines studies of GEMTESA published in the past 3 years Data support GEMTESA’s role as an effective treatment option for overactive bladder (OAB) based on studies including:  Two phase 3 trials (EMPOWUR, EMPOWUR extension) conducted with once daily vibegron 75 mg for the treatment of OAB Additional secondary and […]

Urovant Sciences Announces Positive Topline Results of Phase 2a Trial of its Potential Novel Gene Therapy, URO-902

March 7, 2022 at 11:30 AM EST Study showed clinically meaningful impact on common symptoms of overactive bladder (OAB) compared to placebo from baseline to week 12   IRVINE, Calif. & BASEL, Switzerland – March 7, 2022 – Urovant Sciences, a wholly-owned subsidiary of Sumitovant Biopharma Ltd., today announced positive topline results from its Phase 2a, double-blind, placebo-controlled exploratory […]

Sumitovant and Enzyvant Appoint Bill Symonds, CEO of Altavant Sciences, as Interim Chief Executive Officer of Enzyvant

CAMBRIDGE, Mass. & BASEL, Switzerland, March 2, 2022 – Sumitovant Biopharma and wholly-owned subsidiary Enzyvant, a biopharmaceutical company focused on developing transformative regenerative therapies for patients with rare diseases, today announced the appointment of Bill Symonds, Pharm.D., as interim chief executive officer, effective March 11, 2022. Dr. Symonds has served as the chief executive officer of […]

Myovant Sciences Receives Positive CHMP Opinion for ORGOVYX® (relugolix) for the Treatment of Advanced Prostate Cancer

February 25, 2022 CHMP opinion recommending approval based on data from the global Phase 3 HERO study If approved, ORGOVYX® would be the first and only oral androgen deprivation therapy for advanced hormone-sensitive prostate cancer in Europe Company remains on track to reach agreement with a partner for international rights to relugolix in oncology by […]

Sumitomo Dainippon Pharma and Sumitovant Biopharma Initiate Phase 1 Study on New Drug Candidate for Carbapenem-Resistant Bacterial Infections

Compound inhibits enzymes produced by bacteria that degrade carbapenem antibiotics  LONDON and NEW YORK, February 10, 2022 — Sumitovant Biopharma Ltd., in partnership with its parent company Sumitomo Dainippon Pharma Co., Ltd., recently announced the launch of a phase 1 study in the U.S. on a new drug candidate (“KSP-1007”) for carbapenem-resistant bacterial infections. The […]

Myovant Sciences to Present at Upcoming Investor Conferences

BASEL, Switzerland, Feb. 07, 2022 (GLOBE NEWSWIRE) — Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced that David Marek, Chief Executive Officer of Myovant Sciences, Inc., and other members of the Myovant executive team will participate in a fireside chat at the following investor conferences: 11th Annual SVB Leerink Global Healthcare Conference on Friday, February 18, 2022, […]

Enzyvant Appoints Johanna Rossell as Chief Commercial Officer

Industry veteran brings extensive experience including tissue-based and regenerative therapies CAMBRIDGE, Mass. & BASEL, Switzerland, January 26, 2022 (GLOBE NEWSWIRE) — Enzyvant today announced the appointment of Johanna Rossell as Chief Commercial Officer. Johanna Rossell has an extensive background in the pharmaceutical and healthcare sector, leading multifunctional teams across several geographic markets around the world. […]

Myovant Sciences Announces Financial Results for Third Quarter of Fiscal Year 2021 and Corporate Updates

January 26, 2022 at 6:55 AM ESTPDF Version Third fiscal quarter 2021 total revenues of $54.4 million, including net product revenue of $29.3 million Net product revenue from U.S. sales of ORGOVYX® of $24.4 million, reflecting 40% sequential volume growth compared to second fiscal quarter 2021, partially offset by a lower net price Net product revenue from U.S. sales of MYFEMBREE® of $2.4 million; New-to-brand […]

Urovant Sciences Announces Publication in Advances in Therapy of Analyses of Patient-Perceived Meaningfulness of Improvement in Symptom Reduction for Overactive Bladder Patients Treated with GEMTESA® (vibegron) 75 mg

December 20, 2021 at 12:11 PM EST — Data from the 12-week EMPOWUR trial regarding patient perceptions of improvement of OAB symptoms show that significantly more patients treated once-daily with GEMTESA® (vibegron) experienced patient-perceived improvements due to the reduction in micturition frequency (urination), urinary urgency episodes, and urge urinary incontinence episodes vs. placebo. This analysis supports […]